Purpose To determine whether HMG-CoA reductase inhibitors (statins) are associated with a lower risk of pancreatic cancer. Methods The population included 160,578 postmenopausal women enrolled in the Women's Health Initiative (WHI) in which 385 incident cases of pancreatic cancer were identified over an average of 8.69 (SD ±4.59) years. All diagnoses were confirmed by medical record and pathology review. Information on statin use and other risk factors was collected at baseline and during follow-up. Multivariable-adjusted hazards ratios (HRs) and 95 % confidence intervals (CIs) evaluating the relationship between prior statin use (at baseline only as well as in a time-dependent manner) and risk of pancreatic cancer were computed from Cox proportional hazards regression analyses after adjusting for appropriate confounders. We also evaluated the effect of statin type, potency, lipophilic status, and duration of use. All statistical tests were two-sided. Results Statins were used at baseline by 12,243 (7.5 %) women. The annualized rate of pancreatic cancer in statin users and nonusers, respectively, was 0.0298 versus 0.0271 %. The multivariable-adjusted HR for statin users versus nonusers at baseline was 0.92 and 95 % CI 0.57-1.48. In a time-dependent model, the HR for lowpotency statins was 0.46, 95 % CI 0.20-1.04. There was no significant effect seen by statin lipophilicity or duration of use. Conclusions There was no significant relationship between statins and pancreatic cancer risk in the WHI; however, there was a marginal inverse association noted for low-potency statins. Analyses of larger numbers of cases are needed to further explore this relationship.
Introduction
In 2014, it is estimated that there were 46,420 new cases of pancreatic cancer in the USA with 39,590 deaths as a result of the disease [1] . The estimated 5-year survival rate from 2004 to 2010 was 6.7 % [1] . Given the overall poor survival and the lack of effective treatment options [2] , it is important to explore and consider new agents that can be utilized for chemoprevention and/or treatment of pancreatic cancer [3] .
Statins have known efficacy for cholesterol reduction and prevention of cardiovascular disease [4] , and preclinical studies suggest a potential anticancer effect through inhibition of HMG-CoA reductase leading to down-regulation of downstream products in the mevalonate pathway which are involved in multiple molecular pathways known to be deregulated in cancer including Ras, MEK, PI3K/Akt [5, 6] , Rho kinases [7, 8] , and BCl2 [9] . Since pancreatic cancers frequently contain mutations in the Ras and PI3K/Akt genes [10] [11] [12] , this tumor type may be a potential target for preventative strategies using statins, a hypothesis that is supported by both in vitro [13] and mouse model studies [14, 15] . Despite promising preclinical data, epidemiologic studies of statins and pancreatic cancer have yielded mixed results with the majority showing no association, as reviewed in a recent meta-analysis [16] . However, a reduction in risk was reported in two recent case-control studies [17, 18] and an increase in risk in a cohort analysis [19] .
In this report, we examine the relationship between statins and risk of pancreatic cancer in the WHI. Our hypothesis was that prior statin use would be associated with a reduced risk of pancreatic cancer. The WHI is the largest multicenter longitudinal study of postmenopausal women in the USA with follow-up on cancer diagnoses through September 2012 [20] .
Methods

Study population
The population included 161,808 postmenopausal women age 50-79 enrolled in the WHI clinical trial (CT) and observational study (OS) from 1 October 1993 through 31 December 1998. Study implementation details have been published previously [20] [21] [22] . Follow-up continued from study initiation until planned termination on March 2005 and thereafter for participants providing re-consent with data collection updated through September 2012. We excluded from the analysis 1,228 women with a prior history of pancreatitis as well as two women for whom there was no information on statin use.
Statin exposure
Statin exposure and duration were determined at baseline in the CT and OS participants. The participants were asked to bring all prescription medications to the clinic visit (or first interview at baseline), and each medication name was directly entered from the medication containers into the WHI database, which assigned drug codes using Medispan software (First DataBank, Inc., San Bruno, CA). Statin duration was measured by in-person questionnaire at baseline, and information provided was based on participant self-report. For the current analysis, information on statin duration was only based on baseline data. In order to carry out a time-dependent analysis (see ''Statistical analysis'' section), we utilized reported statin use that was updated in year 3 in the OS and years 1, 3, 6, and 9 in the CT.
Statin intake was defined as use of any 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor. Statins were classified as lipophilic (lovastatin, simvastatin, fluvastatin, atorvastatin) or hydrophilic (pravastatin) [23, 24] and by potency: low potency (fluvastatin and lovastatin), medium potency (pravastatin), and high potency (simvastatin and atorvastatin) [24, 25] .
Outcomes
The outcome of interest was pathologically confirmed invasive pancreatic cancer. Reported cancer cases were initially confirmed by medical record review by trained physician adjudicators at the clinical centers. Final adjudication was done at the Clinical Coordinating Center.
Covariates
Information regarding potential confounding and modifying variables was collected by baseline questionnaire which ascertained socio-demographic characteristics, known risk factors for pancreatic cancer (age, race/ethnicity, smoking status, and history of diabetes mellitus), other variables potentially associated with cancer risk, variables associated with statin use, and other variables associated with healthcare utilization which might impact both statin utilization and cancer detection. Information on baseline food habits was determined by the WHI Food Frequency Questionnaire [26] . The covariates considered are listed in Tables 1 and 2 . The medical history variable includes a personal history of diabetes, high cholesterol, myocardial infarction, angina, and/or pancreatic disease. BMI was adjusted for as a continuous variable. 
Statistical analysis
The characteristics of statin users versus nonusers at baseline as well as pancreatic cases versus non-cases were compared by Chi-square tests. Annualized rates of pancreatic cancer were calculated according to the use of statins at baseline. Planned selected subgroup analyses were conducted by statin use duration as determined at baseline (\1, 1 to \3, and C3 years), statin type, potency, and lipophilic status. Women reporting use of two or more statins were included in analyses that compared statin use to none, but were excluded from analyses that examine details of statin use by type, potency, or lipophilic status. Hazard ratios (HRs) and 95 % confidence intervals (CIs) for risk of pancreatic cancer among statin users versus nonusers were computed from Cox proportional hazards models. Tests for the proportional hazards assumptions were conducted by fitting a Cox model that included statin use and the interaction of statin use with follow-up time, and testing for a zero coefficient on the interaction term. An a priori selection of covariates with a backward elimination using a 10 % level of statistical significance in Cox modeling was utilized to create a final multivariable-adjusted model. The base models were adjusted by age and stratified by WHI trial (hormone therapy, dietary modification, or OS), extension study participation, and age group. The multivariable model was adjusted for age and BMI as continuous variables and ethnicity, smoking status, education, alcohol use, physical activity, [30 % energy intake from fat, waist circumference, current medical care provider, aspirin and NSAID use, self-reported health status, and medical history as categorical variables. Subgroup analyses were conducted to look at the impact of history of diabetes, BMI, and smoking on the relationship between statins and pancreatic cancer risk.
To evaluate the effect of change in statin use over time, final models were rerun by entering statin use as a timedependent exposure and using updated information on statins gathered at year three in the OS and years one, three, six, and nine in the CT. We censored cancer outcomes in OS participants 3 years after the last medication update in order to closely parallel measurement of statin exposure in the CT. All statistical tests were two-sided, and nominal P values of 0.05 or less were regarded as statistically significant. Analyses were performed using Statistical Analysis Software (SAS) version 9.4. Table 1 describes the baseline demographic and clinical characteristics of WHI participants stratified by statin use. Many of the differences noted were statistically significant given the large sample size. There were 12,243 (7.6 %) women who reported statin use at baseline. Of note, statin users were more likely to be older than nonusers (median age 65.6 vs. 63.0 years), report a history of smoking, have a higher BMI and waist circumference, report consuming more than 30 % of energy from fat, and report a history of Table 2 describes the characteristics of pancreatic cases compared with non-cases. There were 381 women diagnosed with pancreatic cancer during the follow-up period. Women with pancreatic cancer were more likely to be older, have a larger waist circumference, consume a higher % of energy from fat, use NSIADS, and report a history of diabetes. Table 3 shows the distribution of statin use at baseline by type, duration, potency, and lipophilicity. Table 4 shows the annualized incidence and HRs of pancreatic cancer by statin use, type, lipophilicity, potency, and duration. The annualized incidence rates of pancreatic cancer among statin users and nonusers were 0.0298 % (median follow-up 8.0 years) and 0.0271 % (median follow-up 8.8 years), respectively. There was no association between statin use at baseline and pancreatic cancer risk (HR 0.92, 95 % CI 0.57-1.48), and there was no significant relationship by statin type, lipophilicity, potency, or duration of use. Table 5 shows the relationship between statin use and pancreatic cancer using a time-dependent model. In this model, lovastatin was associated with a nonsignificant lower risk of pancreatic cancer (HR 0.269, 95 % CI 0.067-1.09). A similar relationship was seen in the subgroup analysis of low-potency statins (lovastatin and fluvastatin), which also revealed a nonsignificant lower risk of pancreatic cancer (HR 0.46, 95 % CI 0.20-1.04). There was no other significant relationship by individual statin type or lipophilicity in the time-dependent analysis. In addition, there was no relationship between statins and pancreatic cancer by current smoking status (yes vs. no), BMI at baseline (\25, 25 to \30, C30), or history of diabetes mellitus (data not shown). In an analysis excluding 28 cases of pancreatic cancer which occurred within 1 year of study enrollment, there were no differences in our findings (data not shown).
Results
Discussion
Overall, in the present study statins were not associated with a reduced risk of pancreatic cancer in the WHI cohort. However, in a time-dependent analysis there was a marginal, nonsignificant reduction in risk of pancreatic cancer associated with lovastatin and the combined grouping of lovastatin and fluvastatin (low-potency statins). There was, however, no significant relationship by lipophilicity or duration of use, and no interaction with BMI, history of diabetes, or smoking history. Ras and PI3K/Akt are mutated in approximately 95 % of pancreatic cancers [10, 12, 27] , and we hypothesized that statins may impact cancer risk through alteration in these pathways [5-9, 14, 28] .
Despite the evidence for biologic plausibility, the majority of clinical evidence does not demonstrate a relationship between statins and pancreatic cancer risk. In a meta-analysis of 16 studies involving 1,692,863 participants and 7,807 pancreatic cancer cases, pooled results revealed a nonsignificant lower risk of pancreatic cancer among users of any statins (RR 0.89, 95 % CI 0.74-1.07). Similar results were obtained in the subgroup analyses for long-term use ([4 years), and a null association was seen for lipophilic statins (RR 1.03, 95 % CI 0.92-1.16) [16] . No specific results were provided in the meta-analysis for users of specific types of statins or by potency. There was, however, a marked heterogeneity of results with one casecontrol study of male veterans contributing the most showing a significantly lower risk of pancreatic cancer (HR 0.37, 95 % CI 0.3-0.46) [18] and an analysis from the Cancer Prevention Study II Nutrition Cohort showing an increased risk of pancreatic cancer (HR 1.33, 95 % CI 1.03-1.72) [19] . There is also a recently published hospitalbased case-control study showing a lower risk of pancreatic cancer among male smokers; however, these results were based on small numbers with only one out of 25 male cases reporting prior use of statins (OR 0.11, 95 % CI 0.01-0.96) [17] . Our results show no significant interaction by smoking history and are consistent with the literature showing no overall effect of statins on risk of pancreatic cancer risk. The suggestion of a lower risk of pancreatic cancer associated with low-potency statins is mostly driven by the effect of lovastatin which is also a lipophilic statin and which is of interest given other studies that suggest that lipophilic statins have a greater anticancer potential than hydrophilic statins [23, 24] .
Prior analyses of statins and cancer in the WHI showed no relationship between statins and breast cancer [29] [31] or melanoma [32] ; however, a similar marginal lower risk of colorectal cancer was seen among prior users of lovastatin [30] .
The strengths of our study include the prospective design and the large and diverse population which included a large sample size (381 cases) and longer period of follow-up than any of the other studies reported in the meta-analysis [16] . In addition, we were able to evaluate the effect of statins by individual type of statin and statin potency. Other strengths include the wellcharacterized risk factors for pancreatic cancer and cardiovascular risk, outcome verification by central review, and serial update of statin use. Limitations include the low prevalence of statin use at baseline, although the time-dependent analysis enabled us to capture changes in statin use over time. Other limitations include lack of information on medication compliance, the fact that statin use was self-reported, collection of medication use at only selected intervals of time, and recall bias. It is also possible that the estimated association between low-potency statins and pancreatic cancer risk is confounded by unknown or unmeasured factors associated with both exposure and outcome. In conclusion, we found no overall association between statin use and pancreatic cancer risk. However, the marginal lower risk associated with lovastatin implies a potential protective effect of low-potency or lipophilic statins. Further studies in larger populations are needed to clarify these findings. 
